The macrophage - a novel system to deliver gene therapy to pathological hypoxia

被引:158
作者
Griffiths, L
Binley, K
Iqball, S
Kan, O
Maxwell, P
Ratcliffe, P
Lewis, C
Harris, A
Kingsman, S
Naylor, S
机构
[1] Oxford BioMedica UK Ltd, Medawar Ctr, Oxford OX4 4GA, England
[2] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England
[3] John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Med Oncol Lab, Oxford OX3 9DU, England
[4] Univ Sheffield, Sch Med, Dept Pathol, Sheffield S10 2RX, S Yorkshire, England
[5] Univ Oxford, Dept Biochem, Retroviral Mol Biol Grp, Oxford OX1 3QU, England
关键词
macrophage; hypoxia; cytochrome P450; cyclophosphamide; gene delivery; adenovirus;
D O I
10.1038/sj.gt.3301058
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The use of activated macrophages in the treatment of cancer has been largely ineffectual. By 'arming' these cells with the ability to express a therapeutic gene we demonstrate significant advances in the efficacy of this approach. We have used a hypoxia-regulated adenoviral vector to transduce human macrophages with either a reporter or a therapeutic gene encoding human cytochrome P4502B6 (CYP2B6). infiltration of transduced macrophages into a tumour spheroid results in induction of gene expression. We demonstrate significant tumour cell killing only in the presence of cyclophosphamide via activation by P4502B6 and show that this can be further targeted to tumours through hypoxia regulated gene expression.
引用
收藏
页码:255 / 262
页数:8
相关论文
共 27 条
  • [1] ALBINA JE, 1995, J IMMUNOL, V155, P4391
  • [2] ANDREESEN R, 1990, CANCER RES, V50, P7450
  • [3] Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives
    Andreesen, R
    Hennemann, B
    Krause, SW
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 64 (04) : 419 - 426
  • [4] Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo
    Bilbao, G
    Feng, MZ
    Rancourt, C
    Jackson, WH
    Curiel, DT
    [J]. FASEB JOURNAL, 1997, 11 (08) : 624 - 634
  • [5] An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer
    Binley, K
    Iqball, S
    Kingsman, A
    Kingsman, S
    Naylor, S
    [J]. GENE THERAPY, 1999, 6 (10) : 1721 - 1727
  • [6] Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
    Brizel, DM
    Sibley, GS
    Prosnitz, LR
    Scher, RL
    Dewhirst, MW
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (02): : 285 - 289
  • [7] BUGELSKI PJ, 1987, CANCER IMMUNOL IMMUN, V24, P93
  • [8] Targeting gene expression to hypoxic tumor cells
    Dachs, GU
    Patterson, AV
    Firth, JD
    Ratcliffe, PJ
    Townsend, KMS
    Stratford, IJ
    Harris, AL
    [J]. NATURE MEDICINE, 1997, 3 (05) : 515 - 520
  • [9] OXYGEN-REGULATED CONTROL ELEMENTS IN THE PHOSPHOGLYCERATE KINASE-1 AND LACTATE-DEHYDROGENASE-A GENES - SIMILARITIES WITH THE ERYTHROPOIETIN 3' ENHANCER
    FIRTH, JD
    EBERT, BL
    PUGH, CW
    RATCLIFFE, PJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) : 6496 - 6500
  • [10] Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor β-1
    Harmey, JH
    Dimitriadis, E
    Kay, E
    Redmond, HP
    Bouchier-Hayes, D
    [J]. ANNALS OF SURGICAL ONCOLOGY, 1998, 5 (03) : 271 - 278